Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 45,431,305*
Stock purchase warrants 1,590,559**
Stock options 6,863,488**
Fully diluted 53,768,202**
Cash  $25.8 million**
Debt Nil**
Trading symbol AVXL
52-week range $1.85 – $5.15*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations 1-844-689-3939
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org
*As of August 9, 2018
**As of June 30, 2018

Forms – Reverse Stock Split
Internal Revenue Service (United States) – Form 8937.
Form_8937_(signed)